ClearPoint Neuro (NASDAQ:CLPT) Announces Quarterly Earnings Results

ClearPoint Neuro (NASDAQ:CLPT) announced its earnings results on Wednesday. The company reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.04), Zacks reports. ClearPoint Neuro had a negative net margin of 69.08% and a negative return on equity of 122.17%. The business had revenue of $12.13 million during the quarter, compared to analyst estimates of $11.97 million.

Here are the key takeaways from ClearPoint Neuro’s conference call:

• ClearPoint Neuro reported record Q1 2026 revenue of $12.1 million, up 43% year over year, with 16% organic growth driven by its core device businesses and the newly added IRRAflow line.
• Gross margin improved to 64% from 60% a year ago, helped by lower excess and obsolete inventory reserves and early benefit from the IRRAS integration.
• The company reaffirmed full-year 2026 revenue guidance of $52 million to $56 million and said sequential growth should continue through the rest of the year, though first-half timing may be uneven.
• Management highlighted progress across all four growth pillars, including new CAL facility studies, the first Asia-Pacific commercial drug delivery procedure, and expansion of the 3.x navigation platform into Europe and Canada.
• ClearPoint said it has successfully integrated IRRAflow operations and expects the business to become cash neutral as early as 2027, supported by cost synergies, facility consolidation, and broader commercial adoption.

ClearPoint Neuro Price Performance

Shares of NASDAQ:CLPT traded down $0.45 during midday trading on Wednesday, reaching $12.19. The company’s stock had a trading volume of 779,626 shares, compared to its average volume of 726,113. ClearPoint Neuro has a fifty-two week low of $8.27 and a fifty-two week high of $30.10. The company has a market capitalization of $365.58 million, a P/E ratio of -13.40 and a beta of 1.29. The company has a debt-to-equity ratio of 1.75, a current ratio of 5.91 and a quick ratio of 5.13. The business’s fifty day simple moving average is $10.32 and its 200-day simple moving average is $13.45.

Institutional Trading of ClearPoint Neuro

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CLPT. Caitong International Asset Management Co. Ltd acquired a new stake in ClearPoint Neuro in the fourth quarter worth about $25,000. BNP Paribas Financial Markets increased its position in ClearPoint Neuro by 2,435.2% in the second quarter. BNP Paribas Financial Markets now owns 2,231 shares of the company’s stock worth $27,000 after purchasing an additional 2,143 shares during the period. Legal & General Group Plc acquired a new stake in ClearPoint Neuro in the second quarter worth about $35,000. Russell Investments Group Ltd. increased its position in ClearPoint Neuro by 1,079.0% in the third quarter. Russell Investments Group Ltd. now owns 2,358 shares of the company’s stock worth $51,000 after purchasing an additional 2,158 shares during the period. Finally, Raymond James Financial Inc. acquired a new stake in ClearPoint Neuro in the second quarter worth about $80,000. 30.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on CLPT shares. Stifel Nicolaus started coverage on ClearPoint Neuro in a research note on Friday, May 8th. They issued a “buy” rating and a $16.00 target price for the company. Weiss Ratings restated a “sell (d-)” rating on shares of ClearPoint Neuro in a research note on Monday, April 20th. Finally, B. Riley Financial raised their target price on ClearPoint Neuro from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday, March 18th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $18.00.

About ClearPoint Neuro

ClearPoint Neuro, Inc is a medical technology company specializing in the development and commercialization of an MRI-guided therapy platform for minimally invasive neurosurgical procedures. Headquartered in Cambridge, Massachusetts, the company’s flagship ClearPoint® SmartFrame™ system enables surgeons to perform accurate and efficient intracranial interventions by providing real-time magnetic resonance imaging feedback. This technology is designed to improve patient safety and outcomes in treatments ranging from deep brain stimulation electrode placement to laser ablation of epileptic foci and brain tumors.

The ClearPoint System integrates hardware, software and imaging capabilities to guide instruments through the brain with submillimeter precision.